A photo of Gang Huang.

Member, Division of Experimental Hematology & Cancer Biology

Associate Professor, UC Department of Pathology and Laboratory Medicine



Biography & Affiliation

Academic Affiliation

Associate Professor, UC Department of Pathology and Laboratory Medicine

Research Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases

Blog Posts

COVID-19 School Study in JAMA Tops Most-Shared Findings From July 2020

Infectious Diseases and Vaccines

COVID-19 School Study in JAMA Tops Most-Shared Findings From July 2020

Gang Huang, PhD, Katherine A. Auger, MD, MSc ...8/11/2020


BS: Peking University, College of Science, Beijing, P.R. China, 1991.

MS: Inner Mongolia University, Graduate School of Science, Huhhort, P.R. China, 1994.  

PhD: Kyoto University, Graduate School of Medicine, Kyoto, Japan, 2001.


Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Chen, L; Long, X; Xu, Q; Tan, J; Wang, G; Cao, Y; Wei, J; Luo, H; Zhu, H; Huang, L; et al. Cellular and Molecular Immunology. 2020; 17:992-994.

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre. Huang, H; Xu, C; Gao, J; Li, B; Qin, T; Xu, Z; Ren, S; Zhang, Y; Jiao, M; Qu, S; et al. Blood Cancer Journal. 2020; 10.

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Cao, Y; Wei, J; Zou, L; Jiang, T; Wang, G; Chen, L; Meng, F; Huang, L; Wang, N; Zhou, X; et al. Journal of Allergy and Clinical Immunology. 2020; 146:137-146.e3.

Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia. Huang, H; Qin, T; Xu, Z; Shi, Z; Li, B; Pan, L; Hu, N; Qu, S; Huang, G; Gale, RP; et al. British Journal of Haematology. 2020; 188:796-800.

The Role of RUNX1 in NF1-Related Tumors and Blood Disorders. Na, Y; Huang, G; Wu, J. Molecules and Cells. 2020; 43:153-159.

The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies. Yokota, A; Huo, L; Lan, F; Wu, J; Huang, G. Molecules and Cells. 2020; 43:145-152.

DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells. Bera, R; Chiu, M; Huang, Y; Huang, G; Lee, Y; Shih, L. Oncogenesis. 2020; 9.

Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Chen, S; Wang, Q; Yu, H; Capitano, ML; Vemula, S; Nabinger, SC; Gao, R; Yao, C; Kobayashi, M; Geng, Z; et al. Nature Communications. 2019; 10.

SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints. Dong, Y; Zhao, X; Feng, X; Zhou, Y; Yan, X; Zhang, Y; Bu, J; Zhan, D; Hayashi, Y; Zhang, Y; et al. Leukemia. 2019; 33:2585-2598.

Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome. Shi, Z; Qin, T; Xu, Z; Li, B; Huang, H; Zhang, H; Fang, L; Pan, L; Hu, N; Qu, S; et al. Leukemia and Lymphoma. 2019; 60:2835-2837.